In ovarian cancer, pathogenic variants in BRCA1, BRCA2, RAD51C, RAD51D, and PALB2 predict PARP inhibitor efficacy, but this has not been established for other HRR-related genes [44, 45]. This evidence concerns the gene PALB2 and ovarian carcinoma.